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Abstract
Introduction: An active area of tobacco regulatory science research focuses on
examining the effects of varying the nicotine content of cigarettes as part of a potential
national policy to lower their nicotine content levels to reduce addiction potential. The
present study examines differences in the behavioral effects of reduced nicotine content
cigarettes related to their menthol status. Menthol is the only cigarette flavoring that is
still legally permissible according to Food and Drug administration regulations.
Methods: Participants were 26 current adult smokers from three populations especially
vulnerable to tobacco use and addiction (economically disadvantaged women, opioiddependent individuals, individuals with affective disorders) dichotomized as menthol
(n=11) or non-menthol (n=15) smokers. Participants completed 14 experimental sessions
following acute smoking abstinence (CO<50% baseline level). Across sessions,
participants smoked four Spectrum research cigarettes (22nd Century Group, Clarence,
NY) with varying nicotine content levels (0.4mg/g, 2.4 mg/g, 5.2 mg/g, 15.8 mg/g) or
their usual brand cigarette. Research cigarettes were mentholated or non-mentholated
corresponding to participants usual brand. Upon completion of smoking, participants
completed tasks measuring reinforcing efficacy, subjective effects, topography, and
withdrawal and craving measures. Repeated Measures Analysis of Variance was used for
all analyses (p<.05).
Results: Main effects of menthol status, as well as interactions of nicotine dose and
menthol were noted across subscales of subjective effects and direct assessments of
reinforcing efficacy. Usual brand mentholated cigarettes produced a profile of equal or
greater relative reinforcing effects than usual brand non-mentholated cigarettes, while
mentholated research cigarettes produced a profile of effects that fell below (i.e., lower
relative reinforcing effects compared to usual brand or non-mentholated cigarettes) those
of non-mentholated research cigarettes.
Conclusions: Mentholated research cigarettes produce a lower profile of reinforcing and
subjective effects, without discernible differences in smoking topography. The potential
impact of mentholation on reinforcing efficacy and subjective effects should be
considered when using Spectrum research cigarettes.
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Comprehensive Literature Review

Despite a steady decline in smoking prevalence since the landmark U.S.
Surgeon’s General report in 1964 highlighting the deleterious health consequences of
smoking, cigarette smoking remains a serious U.S. public health problem. Smoking is
responsible for an estimated 480,000 premature deaths and $300 billion dollars annually
in both health and lost productivity costs (U.S. Department of Health and Human
Services, 2014). To address this public health challenge, the Family Smoking Prevention
and Tobacco Control Act was passed in 2009 giving the Food and Drug Administration
(FDA) regulatory authority over the manufacturing and marketing of cigarettes and other
tobacco products. This Act gives the FDA authority to reduce, although not eliminate, the
amount of nicotine in cigarettes if deemed in the interest of protecting public health.
NICOTINE REDUCTION
There is overwhelming evidence that nicotine is the constituent in tobacco smoke
that promotes chronic smoking and nicotine dependence (U.S Department of Health and
Human Services, 1988, 2012, 2014). Currently, the FDA is supporting research
investigating, among other things, the impact of reducing nicotine content levels in
cigarettes below a hypothesized addiction threshold (Benowitz & Henningfield, 1994).
Research supported by these initiatives has suggested that acute exposure to cigarettes
with reduced nicotine content decreases the reinforcing effects and other subjective
effects of smoking at these lowered doses compared to cigarettes with higher nicotine
contents without evidence of promoting compensatory smoking (Higgins et al., 2017).
Investigations of extended exposure to cigarettes with reduced nicotine content levels
1

illustrate a decrease in cigarettes smoked per day (CPD) and nicotine dependence severity
relative to cigarettes with a nicotine content level similar to what is in commercial
cigarettes (e.g., Donny et al., 2015). This research is being used to help the FDA examine
the feasibility and potential efficacy of a national policy that reduces the maximal
nicotine content of cigarettes to very low levels. Importantly, as smoking rates continue
to decline, certain populations, who may be especially vulnerable to smoking, show
increases in smoking, higher dependence levels, and lower cessation rates (Higgins et
al. 2016; Higgins & Chilcoat 2009; Hiscock et al. 2012).
MENTHOLATION IN CIGARETTES
Other constituents of cigarette tobacco that may have an impact on smoking
prevalence and dependence risk are being considered by the FDA as well. One
constituent that affects a large proportion of current cigarette smokers is cigarette
flavoring (i.e., mentholation). In addition to giving the FDA authority to set nicotine
standards, the 2009 Family Smoking Prevention and Tobacco Control Act grants FDA
authority over flavorings in cigarettes including menthol (Family Smoking Prevention
and Tobacco Control Act, 2009). Currently all flavorings in cigarettes other than menthol
are banned. Approximately one-third of the U.S. cigarette market is made up of mentholflavored cigarettes (Federal Trade Commission Report, 2013). Menthol cigarettes are
distinct from non-menthol cigarettes due to their unique sensory effects, such as the
reported ‘cooling’ that menthol provides. Individuals who smoke menthol cigarettes tend
to do so exclusively and generally express preference for the sensory experience provided
by the menthol cigarette (Kreslake, Wayne, Connolly 2008). As the only flavoring legally
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allowable in cigarettes, it is important to consider the impact mentholation could
potentially have on the acceptability of reduced nicotine content cigarettes.
In the way of background, menthol is a chemical compound derived from the oil
of the peppermint and corn mint plants or can be created synthetically to provide a
distinct mint-like flavor (Tobacco Product and Scientific Advisory Committee (TPSAC)
Report, 2011). Menthol was first added to cigarettes in the mid 1920s, yet did not reach
mainstream popularity until the mid 1930s (Tobacco Product and Scientific Advisory
Committee (TPSAC) Report, 2011). Menthol flavoring is added to cigarettes in a variety
of ways, most commonly by spraying an alcohol based menthol solution on the tobacco
during blending or applying menthol product to the filter during cigarette filter
manufacturing. Other technologies to add menthol to cigarettes include spraying an
alcohol based menthol solution onto the inner foil of the packaging, inserting crushable
mentholated beads in the filter, mentholated threads, or mentholated crushable
microbeads that fill a filler cavity or are mixed into the filter (R.J. Reynolds, Altria Client
Services, 2010). Although cigarettes marketed as non-menthol often have some level of
menthol (< 0.1 mg/cigarette) in the product (Ai et al., 2016), detectable levels of menthol
in cigarettes are approximately 0.6 – 1.5 mg/cigarette (Heck et al., 2010). Recent analyses
of 23 non-menthol and menthol cigarette brands determined that menthol content in
cigarettes advertised as menthol range widely from 2.9 – 19.6 mg/cigarette and menthol
content in non-menthol cigarettes ranges from 0.0002 to 0.07mg/cigarette (Ai et al.,
2016).
An estimated 39% of U.S. current smokers report regular use of mentholated
cigarettes (Villanti et al., 2016). This represents an increase from 35% in 2008-2010
3

(Villanti et al., 2016), suggesting that while overall smoking prevalence continues to
decline, menthol cigarette use does not follow that pattern. Smokers of menthol cigarettes
tend to be younger, non-white, and female relative to non-menthol smokers (Giovino et
al., 2015; Lawrence et al., 2010; SAMSHA, 2011; Villanti et al., 2016). There are mixed
findings on dependence and smoking cessation among menthol smokers (see Hoffman &
Simmons, 2011a and Frost-Pineda, Muhammad-Kah, Rimmer, & Liang, 2014 for
reviews) with some literature suggesting greater nicotine dependence and lower cessation
rates in menthol smokers (Ahijevych & Garrett, 2010; Fagan et al., 2015) and others
suggesting no differences (Hoffman & Sommons, 2011b; Hyland, Garten, Giovino, &
Cummings, 2002).
There is a literature examining the role that mentholation has on the sensory
experience of smoking and how associated responses to smoking, such as craving,
withdrawal, and subjective experience are affected. This literature suggests that
mentholation acts as a cue or discriminative stimulus for menthol smokers and that
removal or altering of that stimulus can affect the smoking experience (Rose & Behm,
2004). A recent study comparing withdrawal and craving reduction among menthol and
non-menthol smokers illustrates this point. When intravenous (IV) nicotine was
administered under acute abstinence to both the menthol and non-menthol smoker
groups, menthol smokers reported significantly less reduction of smoking urges
compared to non-menthol smokers and a trend towards less reduction of withdrawal
symptoms (Devito et al., 2016). Those differences remained after controlling for potential
confounding of race and gender. This blunted response to the IV nicotine in the menthol
relative to non-menthol group suggests that menthol may provide a distinct stimulus
4

profile that at least in part may mediate other effects of smoking such as changes in
craving and withdrawal as outlined above. Considered together, the literature on
mentholation suggests that its potential influence on the smoking experience should be
considered in any research involving menthol smokers.
MENTHOL CONTENT AND NICOTINE REDUCTION
To my knowledge, only two studies have been reported addressing the question of
how smokers of non-menthol versus menthol reduced nicotine content cigarettes may
differ. Pickworth and colleagues (2002) administered three cigarettes with varying
nicotine yield in a double-blind, within-session study; a commercial cigarette with a yield
typical of commercial cigarettes (1.1 mg), a high nicotine yield research cigarette (2.5
mg), and a low nicotine yield research cigarette (0.2 mg). It should be noted that in this
study nicotine yield is used as an indicator of potential nicotine exposure level as opposed
to nicotine content. Nicotine yield is machine-measured exposure to nicotine when a
cigarette is smoked in a standardized way (Federal Trade Commission Report, 2000).
Often smokers will engage in compensatory smoking (e.g., increasing puff volume) to
obtain a greater nicotine yield than the machine-estimated value (see Scherer and Lee
2014 for a review). Thirty-six participants were assigned their preferred mentholation (i.e
menthol or non-menthol) and directed to smoke all three cigarettes over a single
laboratory session. Half of the subjects were regular menthol smokers and half nonmenthol smokers. Ratings of subjective experience were assessed using the Cigarette
Evaluation Questionnaire (CEQ) (Westman et al., 1992) and the Duke Sensory
Questionnaire (Rose & Behm, 2004). Both questionnaires were developed to understand
the sensory and positive subjective effects of smoking. Number of puffs taken for each
5

cigarette and time to smoke each cigarette was examined as a proxy for compensatory
smoking. Physiological measures of heart rate, blood pressure, and changes in carbon
monoxide (CO) were collected as well. No differences by menthol status were reported
for physiological measures and the commercial and high-yield cigarettes produced
greater changes in physiological outcomes than the low-yield cigarette overall. There was
a significant effect of mentholation on subjective effects, although it was restricted to
only the high dose. At the highest nicotine yield cigarette, menthol smokers reported the
cigarette to be less satisfying and provided less relief from craving compared to nonmenthol smokers (Pickworth et al., 2002).
The second study (Hatsukami et al., 2013) was an initial examination of Spectrum
research cigarettes (22nd Century Group), which are currently used exclusively by the
FDA for purposes of examining nicotine content and are the type that is used in the
present study as well. The nicotine content levels in Spectrum cigarettes are altered by
genetically modifying the tobacco. Fifty-one participants smoked four puffs of three
research cigarettes with different nicotine doses (nicotine content 0.4 mg/g, 5.7-5.8 mg/g,
11.4-12.8 mg/g; nicotine yields >.04 mg, 0.3 mg, 0.6 mg, respectively) over the course of
a single session in double-blind, random order. Participants were assigned menthol or
non-menthol cigarettes based on their usual brand preference, with approximately half of
participants (47%) being menthol cigarette smokers. After smoking each cigarette,
participants were given a modified version of the CEQ used by Pickworth and colleagues
where subjective effects of smoking are rated on five subscales (Satisfaction,
Psychological Reward, Enjoyment of Respiratory Tract Sensations, Aversion, and
Craving Reduction). They also assessed a scale of Perceived Health Risk in which
6

participants rated the perceived disease risk of these products as well as the Multiple
Choice Procedure (MCP, Griffiths, Troisi, Silverman, & Mumford, 1993), which assesses
relative reinforcing effects by having participants indicate at what monetary value they
would forego a pack of cigarettes for money. Physiological measures of heart rate and
blood pressure were collected as well.
Overall, reducing nicotine content produced orderly, dose-dependent decreases
across the battery of dependent measures. There were also significant differences in how
the menthol and non-menthol smokers rated the cigarettes. Across doses, menthol
smokers rated the research cigarettes as less satisfying, psychologically rewarding, and
pleasing to the respiratory tract compared to non-menthol smokers. Menthol smokers also
reported smaller craving reductions than non-menthol smokers. A similar finding was
seen with relative reinforcing effects in the MCP, with menthol smokers choosing to
switch to money at a lower monetary value indicating less reinforcing effects compared
to non-menthol smokers. No interaction between menthol status and nicotine dose was
reported suggesting that ratings were shifted downward among menthol compared to
non-menthol smokers across the varying dose cigarettes. That differs from the results in
Pickworth et al. (2002) where differences by menthol status were discerned only at the
high nicotine yield cigarette.
Considered together, these two studies suggest that when nicotine exposure levels
are altered, effects may differ by menthol status of the smoker, although there is some
discrepancy over where in the dose-effect curve such discrepancies are discerned.
Additionally, these two studies leave some gaps where further research is needed. The
first is the use of a comparison of usual brand relative to research cigarette ratings. In the
7

Pickworth et al. (2002) study, participants smoked mentholated or non-mentholated
commercial cigarettes that corresponded with whether their usual brand was mentholated
or non-mentholated, but the cigarettes were not necessarily the participant’s usual brand.
Previous research suggests that when menthol users are switched to another menthol
cigarette of similar nicotine content, subjective ratings can be lower (Strasser et al.,
2013). Therefore, it is important to use the participants’ usual brand, instead of a proxy,
as a true baseline. In the Hatsukami et al. (2013) study, participants first smoke their
usual brand cigarette, but usual brand cigarette findings were not included in the
analyses. Having a usual-brand comparison could be useful to see how smoking
experience of the research cigarettes compares with the participant’s typical smoking
experience. Finally, findings from the prior studies could be extended by examining
effects across additional outcome measures. For example, examining them across wellvalidated measures of smoking topography, craving and withdrawal, and additional
measures of relative reinforcing effects including concurrent choice (Higgins et al., 1994)
and the behavioral-economic Cigarette Purchase Task (Jacobs & Bickel, 1999) could help
to elucidate the range and type of outcomes on which menthol and non-menthol users
vary in response to reduced nicotine cigarettes.
CURRENT STUDY
As discussed above, the overarching goal of FDA-supported research into reduced
nicotine content cigarettes is to determine how individuals may respond to a policy of
reduced nicotine standards. The findings from this program of research could have
substantial impact on current smokers. If menthol and non-menthol smokers respond
differently to reduced nicotine content cigarettes, it is important to determine as
8

thoroughly as possible the nature and breadth of these differences. The aim of the current
investigation is to use a rigorous, within-subject research design to examine differences
by menthol status across a wide range of nicotine doses (0.4mg/g, 2.4mg/g, 5.2mg/g,
15.8mg/g of Spectrum research cigarettes) as well as by usual-brand cigarettes across a
relatively comprehensive battery of outcomes assessing the behavioral pharmacology of
smoking.
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Abstract
Introduction: An active area of tobacco regulatory science research focuses on
examining the effects of varying the nicotine content of cigarettes as part of a potential
national policy to lower their nicotine content levels to reduce addiction potential. The
present study examines differences in the behavioral effects of reduced nicotine content
cigarettes related to their menthol status. Menthol is the only cigarette flavoring that is
still legally permissible according to Food and Drug administration regulations.
Methods: Participants were 26 current adult smokers from three populations especially
vulnerable to tobacco use and addiction (economically disadvantaged women, opioiddependent individuals, individuals with affective disorders) dichotomized as menthol
(n=11) or non-menthol (n=15) smokers. Participants completed 14 experimental sessions
following acute smoking abstinence (CO<50% baseline level). Across sessions,
participants smoked four Spectrum research cigarettes (22nd Century Group, Clarence,
NY) with varying nicotine content levels (0.4mg/g, 2.4 mg/g, 5.2 mg/g, 15.8 mg/g) or
their usual brand cigarette. Research cigarettes were mentholated or non-mentholated
corresponding to participants usual brand. Upon completion of smoking, participants
completed tasks measuring reinforcing efficacy, subjective effects, topography, and
withdrawal and craving measures. Repeated Measures Analysis of Variance was used for
all analyses (p<.05).
Results: Main effects of menthol status, as well as interactions of nicotine dose and
menthol were noted across subscales of subjective effects and direct assessments of
reinforcing efficacy. Usual brand mentholated cigarettes produced a profile of equal or
greater relative reinforcing effects than usual brand non-mentholated cigarettes, while
mentholated research cigarettes produced a profile of effects that fell below (i.e., lower
relative reinforcing effects compared to usual brand or non-mentholated cigarettes) those
of non-mentholated research cigarettes.
Conclusions: Mentholated research cigarettes produce a lower profile of reinforcing and
subjective effects, without discernible differences in smoking topography. The potential
impact of mentholation on reinforcing efficacy and subjective effects should be
considered when using Spectrum research cigarettes.
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Introduction
Despite a steady decline of smoking prevalence since the landmark U.S.
Surgeon’s General report in 1964 highlighting the deleterious health consequences of
smoking, cigarette smoking remains a serious U.S. public health problem. Smoking is
responsible for 480,000 deaths and $300 billion dollars annually in both health and lost
productivity costs (U.S. Department of Health and Human Services, 2014). To address
this public health challenge, the Family Smoking Prevention and Tobacco Control Act
was passed in 2009 giving the Food and Drug Administration (FDA) regulatory authority
over the manufacturing and marketing of cigarettes and other tobacco products. This Act
gives the FDA authority to reduce, although not eliminate, the amount of nicotine in
cigarettes if deemed in the interest of protecting public health.
There is overwhelming evidence that nicotine is the constituent in tobacco smoke
that promotes chronic smoking and nicotine dependence (U.S Department of Health and
Human Services, 1988, 2012, 2014). Currently, the FDA is supporting research
investigating, among other things, the impact of reducing nicotine content levels in
cigarettes below a hypothesized addiction threshold (Benowitz & Henningfield, 1994).
Research supported by these initiatives has suggested that acute exposure to cigarettes
with reduced nicotine content decreases the reinforcing effects and other subjective
effects of smoking at these lowered doses compared to cigarettes with higher nicotine
contents without evidence of promoting compensatory smoking (Higgins et al., 2017).
Investigations of extended exposure to cigarettes with reduced nicotine content levels
illustrate a decrease in cigarettes smoked per day (CPD) and nicotine dependence severity
12

relative to cigarettes with a nicotine content level similar to what is in commercial
cigarettes (e.g., Donny et al., 2015). This research is being used to help the FDA examine
the feasibility and potential efficacy of a national policy that reduces the maximal
nicotine content of cigarettes to very low levels. Importantly, as smoking rates continue
to decline, certain populations, who may be especially vulnerable to smoking, show
increases in smoking, higher dependence levels, and lower cessation rates (Higgins et
al. 2016; Higgins & Chilcoat 2009; Hiscock et al. 2012).
Other constituents of cigarette tobacco that may have an impact on smoking
prevalence and dependence risk are being considered by the FDA as well. One
constituent that affects a large proportion of current cigarette smokers is cigarette
flavoring (i.e., mentholation). In addition to giving the FDA authority to set nicotine
standards, the 2009 Family Smoking Prevention and Tobacco Control Act grants FDA
authority over flavorings in cigarettes including menthol (Family Smoking Prevention
and Tobacco Control Act, 2009). Currently all flavorings in cigarettes other than menthol
are banned. Approximately one-third of the cigarette market is made up of mentholflavored cigarettes (Federal Trade Commission Report, 2013). Menthol cigarettes are
distinct from non-menthol cigarettes due to their unique sensory effects, such as the
reported ‘cooling’ that menthol provides. Individuals who smoke menthol cigarettes tend
to do so exclusively and generally express preference for the sensory experience provided
by the menthol cigarette (Kreslake, Wayne, Connolly 2008). As the only flavoring legally
allowable in cigarettes, it is important to consider the impact mentholation could
potentially have on the acceptability of reduced nicotine content cigarettes.
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In the way of background, menthol is a chemical compound derived from the oil
of the peppermint plant and corn mint plants or can be created synthetically to provide a
distinct mint-like flavor (Tobacco Product and Scientific Advisory Committee (TPSAC)
Report, 2011). Although cigarettes marketed as non-menthol often have some level of
menthol (< 0.1 mg/cigarette) in the product (Ai et al., 2016), detectable levels of menthol
in cigarettes are approximately 0.6 – 1.5 mg/cigarette (Heck et al., 2010) and recent
analyses of 23 non-menthol and menthol cigarette brands determined that menthol
content in cigarettes advertised as menthol ranges widely from 2.9 – 19.6 mg/cigarette
and menthol content in non-menthol cigarettes ranges from 0.0002 to 0.07mg/cigarette
(Ai et al., 2016).
An estimated 39% of U.S. current smokers report regular use of mentholated
cigarettes (Villanti et al., 2016). This represents an increase from 35% in 2008-2010
(Villanti et al., 2016), suggesting that while overall rates of smoking continue to decline,
menthol cigarette use does not follow that pattern. Smokers of menthol cigarettes tend to
be younger, non-white, and female relative to non-menthol smokers (Giovino et al., 2015;
Lawrence et al., 2010; SAMSHA, 2011; Villanti et al., 2016).
There is an existing literature examining the role that mentholation has on the
sensory experience of smoking and how associated responses to smoking, such as
craving, withdrawal, and subjective experience are affected. The literature suggests that
mentholation acts as a cue or discriminative stimulus for menthol smokers and that
removal or altering of that stimulus can affect the smoking experience (Rose & Behm,
2004; Devito et al., 2016). This literature on menthol cigarettes suggests that the potential
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influence of mentholation on the smoking experience should be considered in research in
menthol smokers.
To our knowledge, only two studies relevant to this question have been reported.
The earlier study was an examination of the sensory and physiological effects of
cigarettes that varied in nicotine yield. Pickworth and colleagues (2002) administered
three cigarettes with varying nicotine yield in a double-blind, within-session study; a
commercial cigarette with a yield typical of commercial cigarettes (1.1 mg), a high
nicotine yield research cigarette (2.5 mg), and a low nicotine yield research cigarette (0.2
mg). Thirty-six participants were assigned their preferred mentholation (i.e menthol or
non-menthol) and directed to smoke all three cigarettes over a single laboratory session.
Half of the subjects were menthol smokers and half non-menthol smokers. Ratings of
subjective experience, measured by the Cigarette Evaluation Questionnaire (CEQ)
(Westman et al., 1992) and the Duke Sensory Questionnaire (Rose & Behm, 2004), were
examined. Both questionnaires were developed to understand the sensory and positive
subjective effects of smoking. Number of puffs taken for each cigarette and time to
smoke each cigarette was examined as a proxy for compensatory smoking. Physiological
measures of heart rate, blood pressure, and changes in carbon monoxide (CO) were
collected as well. No differences by menthol status were reported for physiological
measures and the commercial and high-yield cigarettes produced greater changes in
physiological outcomes than the low-yield cigarette overall. There was a significant
effect of mentholation on subjective effects, although it was restricted to only the high
dose. At the highest nicotine yield cigarette, the menthol smokers reported the cigarette
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to be less satisfying and provided less relief from craving compared to non-menthol
smokers (Pickworth et al., 2002).
The second study (Hatsukami et al., 2013) was an initial examination of research
cigarettes called Spectrum cigarettes (22nd Century Group), which are currently used
exclusively by the FDA for purposes of examining nicotine content and are the type of
cigarette used in the present study as well. The nicotine content levels in Spectrum
cigarettes are altered by genetically modifying the tobacco. Fifty-one participants smoked
four puffs of three research cigarettes with different nicotine doses (nicotine content 0.4
mg/g, 5.7-5.8 mg/g, 11.4-12.8 mg/g; nicotine yields >.04 mg, 0.3 mg, 0.6 mg,
respectively) over the course of a single session in double-blind, random order.
Participants were assigned menthol or non-mentholated cigarettes based on their usual
brand preference, with approximately half of participants (47%) being menthol cigarette
smokers. After smoking each cigarette, participants were given a modified version of the
CEQ used by Pickworth and colleagues where subjective effects of smoking are rated on
five subscales (Satisfaction, Psychological Reward, Enjoyment of Respiratory Tract
Sensations, Aversion, and Craving Reduction). They also assessed Perceived Health Risk
in which participants rated the perceived disease risk of these products, as well as the
Multiple Choice Procedure (Griffiths, Troisi, Silverman, & Mumford, 1993), which
assesses the relative reinforcing effects by having participants indicate at what monetary
value they would forgo a pack of cigarettes for money. Physiological measures of heart
rate and blood pressure were collected as well.
Overall, reducing nicotine content produced ordered, dose-dependent decreases
across the battery of dependent measures. There were also significant differences in the
16

ratings of the cigarettes between the menthol and non-menthol smokers. Across doses,
menthol smokers rated the experimental cigarettes as less satisfying, less psychologically
rewarding, and less pleasing to the respiratory tract compared to non-menthol smokers.
Menthol smokers also reported smaller craving reductions than non-menthol smokers. A
similar finding was seen with relative reinforcing effects in the MCP, with menthol
smokers choosing to switch to money at a lower monetary value indicating less
reinforcing effects compared to non-menthol smokers. No interaction between menthol
status and nicotine dose was reported suggesting that ratings were shifted downward
among menthol compared to non-menthol smokers across the varying dose cigarettes.
That differs from the results in Pickworth et al. (2002) where differences by menthol
status were discerned only at high nicotine yield cigarette.
Considered together, these two studies suggest that when nicotine exposure levels
are altered, behavioral effects may differ by menthol status, although there is some
discrepancy over where in the dose-effect curve such discrepancies are discerned.
Additionally, these two studies leave some gaps where future research is needed. The
first is the use of a comparison of usual brand relative to research cigarette ratings, which
neither prior study examined. Having a usual-brand comparison will be useful to see how
smoking experience of the research cigarettes compares with the participant’s typical
smoking experience. Finally, findings from the two prior studies could be extended by
examining effects across additional and more precise outcome measures. For example,
more precise, well-validated measures of smoking topography, measures of craving and
withdrawal, and additional measures of relatively reinforcing effects including concurrent
choice and behavioral-economic tasks could help to elucidate the range and type of
17

outcomes on which menthol and non-menthol users vary in response to reduced nicotine
cigarettes.
As discussed above, the overarching goal of FDA-supported research into reduced
nicotine content cigarettes is to determine how individuals may respond to a policy of
reduced nicotine standards. The findings from this program of research could have
substantial impact on current smokers. If menthol and non-menthol smokers respond
differently to reduced nicotine content cigarettes, it is important to determine as
thoroughly as possible the nature and breadth of these differences. The aim of the current
investigation is to use a rigorous, within-subject research design to examine differences
in behavioral effects by menthol status across a wide range of nicotine content levels
(0.4mg/g, 2.4mg/g, 5.2mg/g, 15.8mg/g) as well as usual-brand cigarettes across a
relatively comprehensive battery of outcomes assessing the behavioral pharmacology of
smoking.
Methods
Participants
Participants were 26 daily smokers from three subpopulations especially
vulnerable to smoking being investigated as part of a larger multi-site study involving
three sites (University of Vermont, John Hopkins University, Brown University). The
subpopulations are women of reproductive age (n = 9), opioid dependent smokers (n =
11), and smokers with affective disorders (n = 6). Inclusion criteria that apply across the
three subpopulations are being 18 years of age or older, smoking greater than or equal to
five cigarettes per day and providing an expired breath carbon monoxide sample of
greater than 8ppm to biochemically verify smoking status. Participants also provided a
negative urine toxicology screen for all illicit substances, except for marijuana (THC) as
18

determined by a multi panel drug test that includes marijuana (THC), cocaine,
barbiturates, benzodiazepines, buprenorphine, opiates, methadone, oxycodone,
phencyclidine, and a breath sample at screening with a breath alcohol level (BAL) of <
.01. Exclusion criteria across the three populations include intention to quit smoking
within the next month, a past month quit attempt from smoking greater than three days,
exclusive use of “roll your own” cigarettes, greater than nine days past month use of
other tobacco products aside from traditional, combustible cigarettes (i.e. smokeless
tobacco products, cigars, e-cigarettes, and related devices), currently pregnant or trying to
become pregnant, currently breastfeeding, symptoms of psychosis or dementia as
determined by the MINI International Neuropsychiatric Interview structured clinical
interview (MINI; Sheehan et al., 1998), current suicidal ideation, and past suicide attempt
(past year for those with affective disorders, past ten years for women of reproductive age
and opioid maintained individuals).
Specific inclusion criteria for socioeconomically disadvantaged women of
reproductive age are females between ages 18-44 with less than Associates’ degree and
not currently enrolled in a degree program. Specific inclusion criteria for opioid
dependent smokers are currently receiving methadone or buprenorphine for the purposes
of opioid maintenance, having maintained a stable methadone or buprenorphine dose for
at least the past thirty days and no more than 30% of past 30 day urine testing positive for
illicit substances as determined by their maintenance provider or study staff if necessary.
Specific inclusion criteria for smokers with affective disorder are current or past 12
months diagnosis of major depressive episode or disorder, dysthymic disorder,
generalized anxiety disorder, post-traumatic stress disorder, obsessive compulsive
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disorder, phobia or panic disorder with or without agoraphobia as determined by the
MINI structured clinical interview. The local Institutional Review Board at each site
approved the study prior to being conducted and each subject signed written consent.
Procedure
Participants completed fourteen 2-4-hr sessions (> 48-hrs between each session).
The 14 sessions were organized into three phases: Phase 1 (Sessions 1-5) an assessment
of smoking topography and subjective effects; Phase 2 (Sessions 6-11) an assessment of
preference between all dose pairs in a concurrent choice schedule; Phase 3 (Sessions 1214) an assessment of preference for each of the three lower doses at a fixed relatively low
response requirement (Fixed-Ratio 10) vs. the highest dose, which was available on a
progressive ratio schedule. Due to technical problems, data from Phase 3 is not included
in the current report.
All visits were conducted under acute abstinence (< 50% baseline breath CO level
collected at screening) and participants were instructed to abstain from smoking 6-8-hrs
prior to the visit to maintain breath CO criterion. Each experimental session was
scheduled within two hours of the time that the baseline experimental visit was scheduled
to keep visits at approximately the same time of day within individual participants. Upon
arrival to the laboratory, participants completed brief physiological measures including
breath CO, BAL, urine toxicology screen for illicit drugs, weight, heart rate, blood
pressure, and urine screen for pregnancy, if applicable. Experimental sessions were
rescheduled for participants who had a breath CO > 50% baseline breath CO level, a
BAL > .03%, or a positive drug screen for both illicit and licit opioids, aside from
prescribed methadone or buprenorphine. Positive drug screens for illicit substances
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excluding opioids resulted in administration of a field sobriety test. If passed, visit was
continued and if failed, the visit was rescheduled. Those with a positive pregnancy test at
any point during the study were withdrawn immediately. All visits occurred > 48-hrs
apart, but within a week of each other.
In Phase 1, participants had basic physiological measures taken upon arrival at the
laboratory followed by two puffs from their usual brand cigarette under staff observation
to equate time since last cigarette across participants. Experimental sessions began 30min following completion of the two puffs. During experimental sessions, participants
were instructed not to eat, drink any beverages other than water, study, or use their
cellular phones. Study staff regularly monitored participants during experimental
sessions. During the 30-min wait period, participants completed two assessments; the
Minnesota Nicotine Withdrawal Scale (MNWS; Hughes & Hatsukami, 1986) and the
Questionnaire of Smoking Urges (QSU-Brief; Cox et al., 2001).
Participants smoked two cigarettes during each visit. Each cigarette was smoked
using a CReSS (Clinical Research Support System) Desktop smoking topography device
(Borgwaldt KC, Richmond, VA). Cigarettes were smoked through a plastic holder that is
attached to two air filled tubes, which lead to a pressure transducer (see Figure 1). The
device measures and records a number of smoking topography measures; (1) total
number of puffs, (2) inter-puff interval (s), (3) puff volume (mL), (4) puff duration (s),
and (5) maximum puff velocity (mL/s).
In Session 1 (Baseline session) participants smoked their usual brand cigarette.
Across the four subsequent experimental sessions in Phase 1 (Sessions 2-5), participants
smoked one of four research cigarettes (0.4mg/g, 2.4mg/g, 5.2mg/g, 15.8mg/g) ad
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libitum. Order of smoking the research cigarettes was randomized across sessions and
participants and was double blind. Research cigarettes were referred to by arbitrary letter
code and were identical in physical appearance. Participants were instructed to smoke the
cigarette as they normally would outside of the laboratory.
Approximately two minutes after extinguishing the first cigarette in Sessions 2-5,
participants lit a second cigarette of the same dose and smoked it in the controlled
manner described below. This second cigarette was designed to introduce participants to
the controlled puffing procedures that were to be used in later phases of the study.
Participants lit the cigarette without inhaling, inserted the cigarette into the cigarette
holder filter, then proceeded to begin inhaling until a 60 mL volume of smoke has been
inhaled which was displayed visually on the computer screen by a counter that increased
as puff volume increased; a second counter immediately next to the running counter
showed the goal volume of 60 mL. Participants were instructed to hold the inhaled puff
in their lungs for 5 s with a timer counting down the duration displayed on a running
counter. Following initiation of a puff, a 30-sec period began to ensure at least that
amount of time between initiation of each puff with the duration again displayed as a
running counter on the computer screen. Participants were instructed to not take the next
puff until all time on the counter had elapsed. Participants followed this regimen until the
cigarette was smoked down to just above the filter.
Upon completion of the second cigarette, participants completed the modified
CEQ (mCEQ; Cappelleri et al., 2007; Westman et al., 1992) and the Cigarette Purchase
Task (CPT; Jacobs & Bickel, 1999; MacKillop et al., 2008). The mCEQ consists of 12
questions on five subscales: Smoking Satisfaction, Enjoyment of Respiratory Tract
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Sensations, Aversion, Craving Reduction, and Psychological Reward. Participants
answered each question using a Likert scale from zero to seven with an answer of zero
indicating “not at all” and an answer of seven indicating “extremely”. The CPT uses an
escalating series of prices to examine the relative reinforcing efficacy of cigarettes by
assessing estimated cigarette consumption at varying levels of economic constraint in a
24-hr period when there is no access to any other nicotine products. In the current study,
the CPT assesses consumption of cigarettes using a 17 point scale evaluating how much
one would smoke when the cost is $0.00/cigarette increasing until cost of the cigarette is
$5.00/cigarette. The CPT generates an individual demand curve using five indices: (a)
Intensity (cigarette smoking when unconstrained by cost), (b) Omax (maximum amount of
money one is willing to spend on smoking per day), (c) Pmax (price at which demand
decreases proportional to price increasing price) (d) Breakpoint (price at which one
would quit smoking rather than incur the cost), and, (e) Elasticity of Demand (overall
sensitivity of smoking rate to price). Additionally, breath CO to measure CO boost, as
well as withdrawal and craving as measured by the MNWS and QSU-brief were
measured every 15 minutes in the hour following completion of smoking the second
cigarette. To measure CO boost, pre-cigarette CO was subtracted from CO from each
value measured at each of the four time points after smoking the cigarette.
Phase 2 consisted of six 4-hr sessions. Upon arrival at the laboratory, participants
followed procedures identical to Phase 1 sessions. Experimental sessions began 30
minutes following completion of the two cigarette puffs that equate time since last
smoking across participants. During the 30-min wait period, participants again completed
the MNWS and the QSU-brief. After 30-min elapsed, participants completed a 3-hr
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concurrent choice task. Upon initiation of the task participants were presented with two
different packs of cigarettes, each with a different letter code. Across the six sessions,
participants experienced all available dose pairs (15.8mg/g v. 0.4 mg/g, 15.8mg/g v. 2.4
mg/g, 15.8mg/g v. 5.2 mg/g, 5.2 mg/g v. 2.4 mg/g, 5.2 mg/g v. 0.4 mg/g, 2.4 mg/g v. 0.4
mg/g) under double-blind conditions with each dose identified by letter code. Order of
dose pairings was randomized across participants and letter codes corresponded to the
letter codes in Phase 1. Participants were instructed to attend to the notes they had made
about each research cigarette to inform their choices during the concurrent task. In the
chamber participants faced a computer screen displaying two 1.25-inch squares. Each
square contained a letter code indicating the two research cigarettes available that
session. Participants were instructed to smoke as much or as little as they want.
Participants indicated a desire to smoke by using a computer mouse to complete 10 clicks
on the letter code of the cigarette they wished to smoke. After completion of the 10
clicks, a 3-min counter appeared on the screen during which the participant could take
two puffs from the selected cigarette in the controlled manner that they had practiced in
Phase 1. Once two puffs were completed, the cigarette was extinguished and the butt
placed in a disposal container. Each smoking choice during a session involved
participants lighting a new cigarette. This controlled puffing procedure is used to control
for any between or within subject differences in smoking topography and to assure that
all puffs are taken from the same part of the cigarette. At completion of the 3-hr session,
participants again complete the MNWS and the QSU-brief.
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Study Product
Study product was Spectrum investigational research cigarettes manufactured by
22nd Century Group (Clarence, NY). Four nicotine dose conditions were investigated
using research cigarettes defined by a nicotine content that was an average across
menthol and non-menthol products (assignment of a menthol or non-menthol product was
based on a participant’s reported usual brand and self-reported preference of menthol or
non-menthol product during the duration of the study): 15.8, 5.2, 2.4, and 0.4 mg/g. For
the 15.8 mg/g dose, the average nicotine content for the menthol product was 15.46 mg/g
and the average nicotine content for non-menthol product was 16.21 mg/g. For the 5.2
mg/g dose, the average nicotine content for the menthol product was 5.22 mg/g and the
nicotine content for average non-menthol product was 5.12 mg/g. For the 2.4 mg/g dose,
the nicotine content for the average menthol product was 2.38 mg/g and the nicotine
content for average non-menthol product was 2.32 mg/g. Finally for the 0.4 mg/g dose,
the average nicotine content for the menthol product was 0.39 mg/g and the average
nicotine content for non-menthol product was 0.38 mg/g. Hereafter, doses will be
referred to by the nicotine content averaged across menthol and non-menthol product:
15.8, 5.2, 2.4, and 0.4 mg/g. The highest dose (15.8 mg/g) is relatively similar to nicotine
content in current commercial cigarettes and the lowest dose (0.4mg/g) is below the
proposed threshold of nicotine dependence (Benowitz & Henningfield, 1994). As
reported by the Center for Disease and Control, average menthol content of the
mentholated research cigarettes ranges from 4.97 mg/cigarette to 7.72 mg/cigarette, with
an average menthol content of 5.98 mg/cigarette at the 0.4mg/g dose, 4.97 mg/cigarette at
the 2.4 mg/g dose, 6.15 mg/cigarette at the 5.2 mg/g dose, and 7.13 mg/cigarette at the
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15.8 dose (Richter et al., 2016). These menthol contents are similar to commercial
mentholated cigarettes (Ai et al., 2016). These cigarettes also differed in the content or
yield of minor alkaloids and nitrosamines and in the application of casings, including
sugars (which were higher in the cigarettes with 15.8 mg/g than in the reduced-nicotine
cigarettes in order to balance the ratio of nicotine to sugar) (Donny et al., 2015).
Statistical Methods
Analysis of differences between menthol and non-menthol in demographic
variables and smoking characteristics were conducted using independent samples t-tests
for continuous variables and Pearson’s chi-square test for categorical variables. For any
categorical variables with categories involving less than five subjects, Fischer’s Exact
Tests were conducted.
Differences in mCEQ, CPT, and smoking topography were determined using
repeated analysis measures of variance, with menthol status (use of non-menthol versus
menthol cigarettes) as the between-subjects factor and nicotine dose (0.4, 2.4, 5.2, 15.8
mg/g, Usual Brand) as the within-subject factor. Analyses of MNWS, QSU, and CO
boost used a similar approach, however, time (pre- and post-cigarette within each
session) was added as an additional within-subject factor and nicotine dose will only
include research cigarette doses (0.4, 2.4, 5.2, 15.8 mg/g) and not Usual Brand.
Significant menthol, time, and dose effects and interactions were followed by post-hoc
tests to fully explain the nature of the differences. The CPT consist of five indices;
Intensity, Breakpoint, Pmax, Omax, and Elasticity. Breakpoint, Pmax, Omax, and
Elasticity were log transformed and the indice Intensity was square root transformed to
meet normality assumptions. Differences between pairings in all the six dose pairings in
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the concurrent choice task were also similarly examined using repeated measures analysis
of variance with menthol status as the between-subjects factor and nicotine dose pair as
the within-subjects factors. Post-hoc testing followed to determine which specific dose
pairs evoke the greatest differences by menthol status with the higher dose chosen at a
statistically significantly higher proportion than chance. Additionally, we examined any
differences in smoking bouts (i.e. number of puffs taken during Phase 2 choice
procedures) by menthol and non-menthol groups. Significance for all tests was set at p <
.05 (two tailed).
Primary Outcomes
We examined differences by menthol status and interactions of menthol status and
nicotine dose in the dependent measures discussed above. More specifically, differences
in the mCEQ, the CPT, the MNWS, QSU-brief, smoking topography indices, and CO
boost were examined from Phase 1. From Phase 2, differences in proportion of choices
allocated to the higher dose across the 6-possible dose pairs were examined, as well as
overall number of smoking bouts per session.
Results
Participant Characteristics
Among the 26 participants, 42% (n = 11) used menthol cigarettes as their usual
brand and 58% (n = 15) used non-menthol cigarettes. Menthol and non-menthol smokers
were mainly female smokers in their mid thirties with the majority having a high school
education or less. Menthol smokers were significantly more likely to be non-white than
non-menthol smokers (Table 1).
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mCEQ
As hypothesized, ratings of menthol cigarettes fell below those of the nonmenthol cigarettes in four of the five mCEQ subscales (Figure 1) with menthol smokers
rating the cigarettes lower than non-menthol smokers. On the Psychological Reward
subscale, there was a main effect of menthol status (F(1,24) = 4.74, p < .05) and an
interaction of menthol and nicotine dose (F(4,96) = 2.90, p < .05) with menthol ratings
overlapping with non-menthol in the usual brand cigarette comparison, but falling below
non-menthol ratings across each of the research cigarette doses. In contrast to the pattern
seen with menthol cigarettes, ratings of the non-menthol cigarettes did not change from
usual-brand levels across the differing research cigarette doses. Similar interactions of
menthol status nicotine dose were seen with the subscales Smoking Satisfaction (F(4,96)
= 2.83, p < .05) and Enjoyment of Respiratory Tract Sensations (F(4,96) = 2.78, p < .05).
Post-hoc testing across the three subscales with menthol by nicotine dose interactions,
showed significantly lower ratings of the research cigarettes compered to usual brand
among menthol (ps < .05) but not non-menthol smokers. Menthol status produced a main
effect on the Craving Reduction subscale with menthol status ratings falling below nonmenthol ratings across all dose comparisons (F(1,24) = 14.24, p < .001). No main effect
of menthol or interaction of menthol status and nicotine dose were observed on the
Aversion subscale. As expected, nicotine dose produced a main effect across all five
mCEQ subscales of the (Fs(4,96) > 2.79, ps < .01).
CPT
There were no main effects of menthol status on the five CPT indices, but there
were three significant interactions of menthol status and nicotine dose on Breakpoint,
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Elasticity, and Omax (Figure 2, Panels A, B, and C respectively), and two trending in the
same direction, Pmax and Intensity (Panels D and E respectively). Regarding the three
indices with significant interactions, ratings of the usual brand menthol cigarette either
overlapped with or indicated greater value than the non-menthol cigarette. Thereafter,
changes in the direction of lower value or reinforcing efficacy relative to usual brand was
seen across the menthol research cigarettes whereas scores of the non-menthol research
cigarettes changed little relative to usual brand (Fs(4,88) = 3.52, ps < .05). Post-hoc
testing revealed menthol smokers reported lower values for the research cigarettes
compared to usual brand (ps < .05) while non-menthol cigarette smokers did not. Similar
patterns were seen with the two indices with non-significant trends towards an interaction
(Fs(4,88) < 2.24, ps = .07). There was a significant main effect of nicotine dose across
four of the five CPT indices (Breakpoint, Elasticity, Omax, and Pmax) (Fs(4,88) > 3.54,
ps < .01).
Direct Testing of Reductions in Addiction Potential
Direct tests of preference across dose pairs in the concurrent-choice arrangement
were of interest for assessing differences in the relative reinforcing effects of the research
cigarettes by menthol status. There was no main effect of menthol status nor a menthol
dose interaction. There was a significant main effect of nicotine dose (F(5,110) = 2.37, p
< .05), with participants preferring the higher of the doses. Post hoc testing revealed that
those differences were attributable to three dose pairs (0.4 v 15.8, 2.4 v 15.8, 2.4 v 5.2)
(Figure 3, Panel A). Exploratory analyses of those same dose pairs by menthol status
indicated that the preference for the higher over the lower dose was significant (p < .05)
among the non-menthol, but not the menthol smokers (Figure 3, Panel B).
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An analysis of the average number of total puffs across dose pairs was examined
by menthol status to determine any differences in overall smoking levels. Mean number
of choices to smoke in the menthol group were somewhat lower than choices of nonmenthol (9.50 + 6.76 versus 16.37 + 13.37) but that difference was not significant (p =
.11).
MNWS and QSU-brief Ratings
Nicotine withdrawal and craving were of interest to determine if there were
differences by menthol status in the amount of relief produced by smoking. Craving and
withdrawal ratings were not collected for usual-brand cigarettes, thus analyses are
restricted to the four research cigarettes.
Regarding the MNWS total score and desire to smoke item, there was no main
effect of menthol status, however there was a main effect of time on both MNWS Total
score (F(4, 96) = 11.39, p < .001), and MNWS desire to smoke item (F(4,94) =29.41, p <
.01) suggesting ratings of withdrawal and craving immediately decreased relative to
baseline (pre-smoking) and increased as time elapsed post-smoking (Figure 4). There was
a significant interaction of menthol status and time with reductions in withdrawal relative
to baseline (pre-smoking) ratings being discernible among the non-menthol smokers but
not the menthol smokers (MNWS Total score: (F(4,96) = 5.39, p < .001; MNWS desire
to smoke item: (Fs(4,96) = 5.36, p < .05). There was no main effect of nicotine dose on
the MNWS, nor interactions of dose with menthol or time.
There was no main effect of menthol status on Factors 1 or 2 of the QSU-brief.
There was a main effect of time on Factors 1 (F(4,95) = 33.08, p < .001) and 2 (F(4,96) =
28.26, p < .001), but no significant interactions of menthol status and time. There were no
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main effects of nicotine dose nor significant interactions of dose, time, and menthol status
on either QSU factor. There was a nonsignificant trend towards an interaction of menthol,
time, and dose for both Factors 1 (F(12,287) = 1.77, p = .05) and 2 (F(12,287) = 1.74, p =
.06) corresponding to the highest research dose cigarette producing larger reductions in
craving at the 15- and 30-minute assessments among non menthol compared to menthol
smokers (data not shown).
Smoking Topography and CO Boost
Smoking topography and CO boost were of interest due to potential concerns of
low nicotine content cigarettes increasing compensatory smoking (i.e. larger puff volume,
longer puff duration) and the possibility of differences in this behavior by menthol status.
Smoking topography was examined across usual brand cigarettes and the research
cigarettes, while CO boost was restricted to only the research cigarettes.
Across the five indices of smoking topography, there were no main effects of
menthol or menthol by nicotine dose interactions, however there was a non-significant
trend towards a main effect of menthol status for Mean Puff Volume (F(1,16) = 4.32, p =
.05) corresponding to a lower puff volume among menthol smokers relative to nonmenthol smokers. There was a main effect of nicotine dose on Inter-puff Interval (F(4,60)
= 2.57, p < .05), but no other main effects of nicotine dose across the remaining indices
(Mean Puff Volume, Puff Duration, Number of Puff, Maximum Flow Rate) (data not
shown).
In regards to CO boost following acute exposure, there was no significant effect
of menthol status, dose, or menthol by dose interactions. There was a significant main
effect of time (F(3,288) = 8.92, p < .001) with CO levels decreasing across time (data not
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shown). Overall, these results show no evidence of compensatory smoking by menthol
status or dose.
Effect of Race on Menthol
It is important to note that although menthol and non-menthol smokers differed
significantly by race, we were unable to control for race in the analyses due to the
homogenous non-menthol sample (i.e. all identifying as Caucasian). To explore the
possibility that differences in the mCEQ, CPT, and concurrent choice testing (Phase 2
dose comparisons) may have been an artifact of including racial minorities in the menthol
but not the non-menthol conditions, we plotted results restricting the data to on
participants who identified as Caucasian (Figure 5). Patterns seen in the complete data
persisted in the sample restrict to Caucasian only, suggesting that the menthol status
differences were not attributable to racial differences between the menthol and nonmenthol conditions.
Conclusions
Overall, the results from this within-subjects study of acute exposure to varying
nicotine content cigarette suggests that menthol smokers respond differently than nonmenthol smokers and those differences follow two distinct patterns. The first pattern is a
reduced acceptability of the research cigarettes in menthol compared to non-menthol
smokers. This lowered response to the research cigarettes across doses among the
menthol relative to non-menthol smokers is seen across measures of positive subjective
effects, withdrawal and craving ratings, and reinforcing efficacy. The findings from both
the subjective ratings and reinforcing efficacy are consistent with the results reported by
Hatsukami et al. (2013) where menthol smokers showed less pleasurable subjective and
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reinforcing effects of research cigarettes compared to non-menthol smokers across
multiple doses of Spectrum research cigarettes. The present results also extended those
results by demonstrating that menthol smokers also report reduced relief from nicotine
withdrawal and desire to smoke compared to non-menthol smokers.
A second pattern seen in the present results is that menthol smokers compared to
non-menthol rate the research cigarettes considerably less satisfying and reinforcing than
their usual brand cigarette whereas non-menthol smokers did that to a lesser extent. This
difference between menthol and non-menthol smokers was observed on the CPT and the
mCEQ measures. To our knowledge, comparisons of usual brand and research cigarettes
by menthol status have not been reported previously.
There are several possible explanations for why these differences by menthol
status may occur. One possibility is that they are attributable to participant self-selection
into the menthol and non-menthol categories. While we cannot rule out that possibility
regarding participant characteristics not assessed in this study, among those
characteristics that were compared between menthol and non-menthol smokers, only race
differed significantly. We could not control for race statistically but when results were
examined among only Caucasians, similar patterns of menthol versus non-menthol
differences remained discernible (See Results and Figure 5), rendering confounding by
race as an inadequate account of the results.
Another potential explanation is that the menthol content differs between
commercially marketed cigarettes and the Spectrum research cigarettes. However, the
most recent analyses of commercially marketed and Spectrum cigarettes (Ai et al., 2016 –
currently marketed cigarettes; Richter et al., 2016 – Spectrum cigarettes) suggest that
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Spectrum research cigarettes fall well within the middle of the range of menthol content
levels (See Ai et al., 2016 for most up to date analyses). In the current study, average
menthol content of usual brand cigarettes among menthol smokers was 4.99 (+ .194)
mg/cigarette and the Spectrum cigarettes used in the current study had an average
menthol content of 6.25 (+ .472) mg/cigarette. Although menthol content of usual brand
was slightly lower than Spectrum cigarettes, both of these values are well within range of
“normal” menthol content reported by Ai et al (2016). None of the menthol smokers in
our sample for whom we had data had menthol contents that were outliers (Range: 3.84 –
5.30), although menthol content of usual brand in the current study was only available for
8/11 (73%) of the menthol smokers.
A final possible explanation for the findings could be greater unwillingness to
switch products among menthol compared to non-menthol smokers. Although data
examining this is sparse, Strasser et al. (2013) showed decreases in satisfaction among
menthol smokers when they were switched from their usual brand to a different
commercial mentholated product (Camel Crush). These results in combination with
findings from the current study suggest that this lowered rating of the research cigarette
relative to usual brand may not be specific to Spectrum cigarettes, but may be a
characteristic of menthol smokers. More research comparing brand switching between
menthol and non-menthol smokers is needed to support this conclusion.
The present study has several limitations that merit mention. One that was
discussed above is the inability to control for racial differences in the sample, although
excluding minorities from the analyses did not appear to alter the pattern of results to any
meaningful extent. Another limitation is the relatively small sample size and one that was
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restricted to populations who are especially vulnerable to smoking. However, the results
were sufficiently robust to discern statistically significant results across multiple
dependent measures and the results were consistent with prior studies using other
populations. These limitations notwithstanding, the present findings suggest that
mentholated Spectrum research cigarettes produce less pleasurable subjective effects, less
relief from withdrawal and craving, and lower reinforcing efficacy among smokers whose
usual brand is mentholated compared to non-mentholated. Further research will be
necessary to determine why this difference is occurring, but researchers involved in
tobacco regulatory science should be aware of this replicable observation and should
consider its implications when conducting research with menthol smokers. Does this
difference occur because Spectrum cigarettes are overall less palatable to menthol
smokers due to some limitation of the research cigarette or is it because menthol smokers
are less likely to be amenable to switching brands more generally? These are important
questions to resolve that have potentially important implications for tobacco regulatory
research.
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Table 1. Demographics
Menthol
(n =11)
35.73 + 12.06
72.7%
55%

Non-Menthol
(n = 15)
37.4 + 10.12
80%
100%

p value

.7
Age (M + SD)
.67
Gender (% Female)
.03
Race (% White)
1.0
Education (%)
Some High School
27.3%
20%
High School
45.5%
40%
Grad./Equivalent
Some College/2-Yr
27.3%
33.3%
Degree
College Graduate/4-Yr
0%
6.7%
Degree
.13
Marital Status (%)
46.7%
Never Married
90.9%
13.3%
Remarried
0%
20.0%
Separated
0%
6.7%
Divorced
9.1%
13.3%
Widowed
0%
Cigarettes per Day (M +
16.46 + 7.78
18.27 + 11.8
.66
SD)
1.19 + 0.27
.59
Nicotine Yield (M + SD)
1.25 + 0.21
.4
Cigarette Type (%)
78.6%
Full Flavor
90.9%
21.4%
Light
9.1%
Age Started Smoking
15 + 2.05
15.47 + 2.13
.58
Regularly (M + SD)
Fagerström Test for
Nicotine Dependence (M +
4.63 + 2.24
5.53 + 2.97
.41
SD)
Note. Values in the table are reported as means + standard deviations unless otherwise
noted. Nicotine yield values come from the Federal Trade Commission’s Tar, Nicotine,
and Carbon Monoxide Report from 1999-2005. Data on cigarette type and yield was not
available for 1 participant.
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Figure Legends
Figure 1. Panels A-E: Mean + SEM for Modified Cigarette Evaluation Scale for menthol
and non-menthol across usual brand (UB) and the four research cigarettes (0.4mg/g,
2.4mg/g, 5.2mg/g, 15.8mg/g). A main effect of nicotine dose was seen across subscales, a
main effect of menthol status was seen at the Craving Reduction subscale (Panel D), and
an nicotine dose menthol interaction effect was seen at Smoking Satisfaction(Panel A),
Psychological Reward (Panel B), and Enjoyment of Respiratory Tract Sensations (Panel
C). An asterisk (*) indicates a significant effect of group at doses in subscales with an
interaction.
Figure 2. Panels A-E: Mean + SEM for the Cigarette Purchase Task for menthol and
non-menthol across usual brand (UB) and the four research cigarettes (0.4mg/g, 2.4mg/g,
5.2mg/g, 15.8mg/g). Panel A: Breakpoint (estimated price at which participants would
quit smoking rather than incur its costs).Panel B: Elasticity(estimated overall sensitivity
of demand to price increases). Panel C: Omax (estimated maximal expenditure
participants were willing to incur for smoking in one day). Panel D: Pmax (estimated
price where demand begins to decrease proportional to price increases). Panel E:
Intensity (estimated consumption levels across prices ranging from $0 to $40/cigarette).
A main effect of nicotine dose was seen for four of the five indices; Breakpoint (Panel
A), Elasticity (Panel B), Pmax (Panel C), Omax (Panel D) and a nicotine dose menthol
interaction was seen at Breakpoint, Omax, Pmax. Breakpoint (Panel A), Elasticity (Panel
B), Omax (Panel C), and Pmax (Panel D) are all log transformed and Intensity (Panel E)
is square root transformed. No significant effect of group was seen at doses in indices
with an interaction effect.
Figure 3. Mean proportion of choices for three nicotine dose pairs across concurrent
choice sessions. Data points are mean across participants by menthol status and error bars
represent + SEM. The varying two-dose comparisons are shown on the x-axis with mean
proportion of choice allocated to each shown on the y-axis. Panel A: Proportion of
choices across dose pairs across all subjects. Panel B: Proportion of choices across dose
pairs by menthol and non-menthol smokers. Asterisks (*) indicate that the higher dose
was chosen at significantly greater than chance level.
Figure 4. Mean + SEM for the Minnesota Nicotine Withdrawal Scale Total Score and
restricted to one item; Desire for menthol and non-menthol pre smoking and across time
points post smoking (15, 30, 45, 60 minutes) and across four research cigarettes
(0.4mg/g, 2.4mg/g, 5.2mg/g, 15.8mg/g). Data points are mean across participants by
menthol status and error bars represent + SEM. Panel A: MNWS Total Score across
menthol subjects. Panel B: MNWS Total Score across non-menthol subjects. Panel C:
MNWS Desire Item across menthol subjects. Panel D: MNWS Desire Item across nonmenthol subjects.
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Figure 5. Comparison of menthol data including all subjects and restricted to include
only white smokers. Panel A: Mean + SEM for the subscale Smoking Satisfaction on the
Modified Cigarette Evaluation Scale for menthol and non-menthol across usual brand
(UB) and the four research cigarettes (0.4mg/g, 2.4mg/g, 5.2mg/g, 15.8mg/g) including
all menthol subjects.
Panel B: Mean + SEM for the subscale Smoking Satisfaction on the Modified Cigarette
Evaluation Scale for menthol and non-menthol across usual brand and the four research
cigarettes (0.4mg/g, 2.4mg/g, 5.2mg/g, 15.8mg/g) including only white menthol subjects.
Panel C: Mean + SEM for the Cigarette Purchase Task indice Breakpoint for menthol and
non-menthol across usual brand and the four research cigarettes (0.4mg/g, 2.4mg/g,
5.2mg/g, 15.8mg/g) including all menthol subjects.
Panel D: Mean + SEM for the Cigarette Purchase Task indice Breakpoint for menthol and
non-menthol across usual brand and the four research cigarettes (0.4mg/g, 2.4mg/g,
5.2mg/g, 15.8mg/g) including only white menthol subjects.
Panel E: Mean proportion of choices by menthol status allocated to the different nicotine
dose cigarettes across three 3-hour two-dose concurrent choice sessions included all
menthol subjects. Data points are mean across participants by menthol status and error
bars represent + SEM.
Panel F: Mean proportion of choices by menthol status allocated to the different nicotine
dose cigarettes across three 3-hour two-dose concurrent choice sessions included only
white menthol subjects. Data points are mean across participants by menthol status and
error bars represent + SEM.
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Figure 1. mCEQ Subscales by Menthol Status Across Dose
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Figure 2. CPT Indices by Menthol Status Across Dose
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Figure 3. Concurrent Choice Test Across Dose Pairs
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Figure 5. Comparison of Limited Sample for Examination of Effect of Race

43

Comprehensive Bibliography
Altria Client Services. Background Information to: Tobacco Products Advisory
Committee: Menthol discussion . TPSAC submission July 15–16, 2010. Accessed
at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting
Materials/TobaccoProductsScientificAdvisoryCommittee/UCM218779.pdf.
Ahijevych, K., & Garrett, B. E. (2010). The role of menthol in cigarettes as a reinforcer
of smoking behavior. Nicotine & Tobacco Research, 12(Suppl 2), S110-S116.
doi: 10.1093/ntr/ntq203
Ai, J., Taylor, K.M., Lisko, J.G., Tran, H., Watson, C.H., & Holman, M.R. (2016).
Menthol content in the US marketed cigarettes. Nicotine & Tobacco Research,
18(7), 1575-1580. doi: 10.1093/ntr/ntv162
Baker, T. B., Piper, M. E., McCarthy, D. E., Bolt, D. M., Smith, S. S., Kim, S-Y., …&
Toll, B. A. (2007). Time to first cigarette in the morning as an index of ability to
quit smoking: Implications for nicotine dependence. Nicotine & Tobacco
Research, 9(Suppl 4), S555-S570. doi: 10.1080/14622200701673480
Benowitz N.L., & Henningfield J.E. (1994). Establishing a nicotine threshold for
addiction: the implications for tobacco regulation. New England Journal of
Medicine, 331, 123-5.
Cappelleri J.C., Bushmakin A.G., Baker C.L., Merikle E., Olufade A.O., & Gilbert D.G.
(2007). Confirmatory factor analyses and reliability of the modified cigarette
evaluation questionnaire. Addictive Behaviors, 32, 912-923.
Cox L.S., Tiffany S.T., & Christen A.G. (2001). Evaluation of the brief questionnaire of
smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine &
Tobacco Research, 3, 7-16.
Devito, E.E., Valentine, G.W., Herman, A.I., Jensen, K.P., & Sofuoglu, M. (2016). Effect
of menthol-preferring status on response to intravenous nicotine. Tobacco
Regulatory Science, 2(4), 317-328. doi: http://dx.doi.org/10.18001/TRS.2.4.4
Donny E.C., Denlinger R.L., Tidey J.W., Koopmeiners J.S., Benowitz N.L., Vandrey
R.G., …& Hatsukami D.K. (2015). Randomized trial of reduced nicotine
standards for cigarettes. New England Journal of Medicine, 373, 1340-9. doi:
10.1056/NEIMsa1502403
Family Smoking Prevention and Tobacco Control Act (H.R. 1256) (2009)
https://www.govtrack.us/congress/bills/111/hr1256/text. Accessed 9/9/2016.
44

Fagan, P., Pohkrel, P., Herzog, T., Pagano, I., Vallone, D., Trinidad, D. R., …&
Moolchan, E. (2015). Comparisons of three nicotine dependence scales in a
multiethnic samples of young adult menthol and non-menthol smokers. Drug &
Alcohol Dependence, 149, 203-211. doi: 10.1016/j.drugalcdep.2015.02.005
Federal Trade Commission. (2000). “Tar,” Nicotine, and Carbon Monoxide of the
Smoker of 1294 Varieties of Domestic Cigarettes for the Year 1998. Washington,
D.C. Federal Trade Commission.
Federal Trade Commission (2013). Federal Trade Commission Cigarette Report for
2013. Washington, D.C. Federal Trade Commission.
Frost-Pineda, K., Muhammad-Kah, R., Rimmer, L., & Liang, Q. (2014). Predictors,
indicators, and validated measures of dependence in menthol smokers. Journal of
Addictive Diseases, 33, 94-113. doi: 10.1080/10550887.2014.909696
Giovino, G.A., Villanti, A.C., Mowery, P.D., Sevilimedu, V., Niaura, R.S., Vallone,
D.M., & Abrams, D.B. (2015). Differential trends in cigarette smoking in the
USA: is menthol slowing progress? Tobacco Control, 24, 28-37. doi:
10.1136/tobaccocontrol-2013-051159
Griffiths, R.R., Troisi, J.R., Silverman, K., & Mumford, G.K. (1993). Multiple-choice
procedure: an efficient approach for investigating drug reinforcement in humans.
Behavioural Pharmacology, 4(1), 3-13.
Hatsukami, D.K., Heishman, S.J., Isaksson Vogel, R., Denlinger, R.L., Roper-Batker,
A.N., Mackowick, K.M., …& Donny, E. (2013). Dose-response effects of
spectrum research cigarettes. Nicotine & Tobacco Research, 15(6), 1113-1121.
doi:10.1039/ntr/nts247
Heck, J.D. (2010). A review and assessment of menthol employed as a cigarette flavoring
ingredient. Food and Chemical Toxicology, 48, S1-S38. doi:
10.1016/j.fct.2009.11.002
Higgins, S.T., Bickel, W. K., & Hughes, J. R. (1994). Influence of an alternative
reinforcer. Life Science, 55(3), 179-187.
Higgins S.T. & Chilcoat H. (2009). Women and smoking: an interdisciplinary
examination of socioeconomic influences. Drug & Alcohol Dependence,
104(Suppl 1):S1–S5
Higgins, S.T., Heil, S.H., Badger, G. J., Skelly, J. M., Solomon, L. J., & Bernstein, I. M.
(2009). Educational disadvantage and cigarette smoking during pregnancy. Drug
& Alcohol Dependence, 104(Suppl 1), S100-S105.
45

Higgins, S. T., Kurti, A. N., Redner, R., White, T. J., Keith, D. R., Gaalema, D. E.,
Sprague, B. L.,…& Priest, J.S. (2016). Co-occurring risk factors for current
cigarette smoking in a US nationally representative samples. Preventive Medicine,
92, 110-117. doi: 10.1016/j.ypmed.2016.02.025
Higgins, S.T., Heil, S.H., Sigmon, S.C., Tidey, J.W., Gaalema, D.E., Stitzer, M.L., …&
Pacek, L.R. (2017). Response to varying the nicotine content of cigarettes in
vulnerable populations: an initial experimental examination of acute effects.
Psychopharmacology, 234(1), 89-98. doi: 10.1007/s00213-016-4438
Hiscock, R., Bauld, L., Fidler, J.A., & Mufano, M. (2012). Socioeconomic status and
smoking: a review. Annals of the New York Academy of Science, 1248
Hoffman, A. C., & Simmons, D. (2011a). Menthol cigarette smoking and nicotine
dependence. Tobacco Induced Diseases, 9(Suppl 1), S5. doi: 10.1186/1617-96259-S1-S6
Hoffman, A.C., & Simmons, D. (2011b). Menthol cigarettes and smoking cessation
behavior. Tobacco Induced Diseases, 9(Suppl 1), S6. doi: 10.1186/1617-9625-9S1-S6.
Hser, Y. I., Hoffman, V., Grella, C. E., & Anglin, M. D. (2001). A 33-year follow-up of
narcotics addicts. Arch Gen Psychiatry, 58, 508-513.
Hughes J.R., & Hatsukami D. (1986). Signs and symptoms of tobacco withdrawal.
Archives of General Psychiatry, 43, 289–294.
Hyland, A., Garten, S., Giovino, G. A., & Cummings, K. M. (2002). Mentholated
cigarettes and smoking cessation: findings from COMMIT. Tobacco Control, 11,
135-139.
Jacobs E.A., & Bickel W.K. (1999). Modeling consumption in the clinic using
simulation procedures: demand for heroin and cigarettes in opioid-dependent
outpatients. Experimental and Clinical Psychopharmacology, 7, 412-26.
Kreslake, J.M., Wayne, G.F., & Connolly, G.N. (2008). The menthol smoker: tobacco
industry research on consumer sensory perception and its role in smoking
behavior. Nicotine and Tobacco Research, 10(4), 705-715. doi:
10.1080/14622200801979134
Lasser, K., Boyd, J. W., Woolhandler, S., Himmelstein, D. U., McCormick, D., & Bor,
D. H. (2000). Smoking and mental illness: a population based prevalence study.
Journal of American Medical Association, 284, 2606-2610.

46

Lawerence, D., Mitrou, F., & Zubrick, S. R. (2009). Smoking and mental illness: results
from population surveys in Australia and the United States. BMC Public Health,
9, 285.
Lawrence, D., Rose, A., Fagan, P., Moolchan, E.T., Gibson, J.T., & Backinger, C.L.
(2010). National patterns and correlates of mentholated cigarette use in the United
States. Addiction, 105(Suppl 1), 13-31. doi: 10.1111/j.1360-0443.2010.03203
MacKillop J., Murphy J.G., Ray L.A., Eisenberg D.T., Lisman S.A., Lum J.K., & Wilson
D.S. (2008). Further validation of the cigarette purchase task for assessing the
relative reinforcing efficacy of nicotine in college smokers. Experimental and
Clinical Psychopharmacology, 16, 57-65.
Pickworth, W.B., Moolchan, E.T., Berlin, I., & Murty, R. (2002). Sensory and
physiologic effects of menthol and nonmenthol cigarettes with differing nicotine
delivery. Pharmacology Biochemistry and Behavior, 71, 55-61.
Richter, P., Pappas, R.S., Bravo, R., Lisko, J.G., Damian, M., Gonzalez-Jimenez, N., …&
Watson, C.H. (2016). Characterization of SPECTRUM variable nicotine research
cigarettes. Tobacco Regulatory Science, 2(2), 94-105. doi:
http://dx.doi.org/10.18001 /TRS.2.2.1
Rose, J. E., & Behm, F. M. (2004). Extinguishing the rewarding value of smoke cues:
Pharmacological and behavioral treatments. Nicotine & Tobacco Research, 6(3),
523-532. doi: 10.1080/14622200410001696501
Scherer, G., Lee, P.N. (2014). Smoking behavior and compensation: A review of the
literature with meta-analysis. Regulatory Toxicology and Pharmacology, 70, 615628. doi:http://dx.doi.org/10.1016/j.yrtph.2014.09.008
Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Dunbar
G.C. (1998). The Mini-International Neuropsychiatric Intervewi (MINI): the
development and validation of a structured diagnostic psychiatric interview for
DSM-IV and ICD-10. Journal of Clinical Psychiatry.
Strasser, A.A., Ashare, R.L., Kaufman, M., Tang, K.Z., Clementina Mesaros, A., & Blair,
I.A. (2013). The effect of menthol on cigarette smoking behaviors, biomarkers,
and subjective responses. Cancer Epidemiology, Biomarkers, & Prevention,
22(3), 382-389. doi: 10.1158/1055-9965.EPI-12-1097
Substance Abuse and Mental Health Services Administration. (2011). Recent The
National Survey on Drug Use and Health: Trends in Menthol Cigarette Use.
Rockville, MD. S Substance Abuse and Mental Health Services Administration.
Accessed 9/1/2016.
47

Tobacco Products Scientific Advisory Committee. (2011). Menthol Cigarettes and Public
Health: Review of the Scientific Evidence and Recommendations. Washington,
D.C. Food & Drug Administration.
U.S. Department of Health and Human Services. (1988). The Health Consequences of
Smoking – Nicotine Addiction: A Report of the Surgeon General. Atlanta, GA:
U.S. Department of Health and Human Services, Centers for Disease Control and
Prevention, National Center for Chronic Disease Prevention and Health
Promotion, Office on Smoking and Health.
U.S. Department of Health and Human Services.(2012). Preventing Tobacco Use Among
Youth and Young Adults: A Report of the Surgeon General. Atlanta, GA: U.S.
Department of Health and Human Services, Centers for Disease Control and
Prevention, National Center for Chronic Disease Prevention and Health
Promotion, Office on Smoking and Health.
U.S. Department of Health and Human Services. (2014). The Health Consequences of
Smoking---50 Years of Progress: A Report of the Surgeon General. Atlanta, GA:
U.S. Department of Health and Human Services, Centers for Disease Control and
Prevention, National Center for Chronic Disease Prevention and Health
Promotion, Office on Smoking and Health.
Villanti, A.C., Mowery, P.D., Delnevo, C.D., Niaura, R.S., Abrams, D.B., & Giovino,
G.A. (2016). Changes in prevalence and correlates of menthol cigarette use in the
USA, 2004-2014. Tobacco Control, 24, 14-20. doi: 10.1136/tobaccocontrol-2016053329
Westman, E.C., Levin, E.D., & Rose, J.E. (1992). Smoking while wearing the nicotine
patch: is smoking harmful? Clinical Research, 40, 871-880.

48

